Vicore Pharma Holding AB VCRE
Vicore Pharma Holding AB (Nasdaq: VCRE) is a respiratory drug developer. Its lead program, buloxibutid, is in Phase 2 for idiopathic pulmonary fibrosis (IPF). Its next catalyst on record is buloxibutid: ASPIRE trial remains on track to report 52-week topline results in mid-2027. (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: buloxibutid — ASPIRE trial remains on track to report 52-week topline results in mid-2027. (H1 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| buloxibutid (AT2 receptor agonist) | idiopathic pulmonary fibrosis | small molecule | Phase 2 |
| Next-generation ATRAGs (AT2 receptor agonists) | — | small molecule | Pre-clinical |
Recent results and decisions
- Oct 22, 2026positive ASPIRE trial passes pre-planned futility analysis with iDMC recommending continuation without modification; 52-week topline results expected mid-2027.
Passing this futility analysis is an important milestone that allows ASPIRE to continue as designed.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 respiratory companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.